Piramal offers a fast-track early stage development service for your ADC programmes. Whether you are selecting your candidate mAb, linker or toxin, we have a programme that will meet your needs. Tailored to perfection.
Cost-effective Proof-of-Concept conjugation service to demonstrate the viability of cytotoxic drugs or monoclonal antibodies for use as therapeutic ADCs.
Piramal's Core Strengths
Client Antibodies for Suitability for Conjugation
Client Cytotoxic or Linker Technologies
ADC Standards to Benchmark Client Materials
Piramal Pharma Solutions
Earls Road, Grangemouth
Stirlingshire, FK3 8XG
Tel: +44 (0)1324 494 853